TRIM62 and inflammatory bowel disease: While the lack of TRIM62-mediated activation is protective in the context of inappropriate intestinal inflammation and may represent a target for therapeutic intervention in IBD (53), these mutations would be predicted to negatively affect antifungal immunity, since Trim62−/− animals are unable to control fungal growth and succumb to infection significantly faster compared to their wild-type counterparts (52).